The Perlin lab at the Hackensack Meridian Health Center for Discovery and Innovation (HMH-CDI; https://hmh-cdi.org) seeks a highly motivated postdoctoral researcher to study the determinants of emergence of drug resistance in fungal pathogen Candida glabrata. The CDI, located in Nutley, NJ (15 minutes from Manhattan), is a new academic-based entrepreneurial center that harnesses current innovations in science to prevent, reduce and cure acute and chronic diseases related to cancer, infectious diseases and other life-threatening and debilitating conditions. The overarching research focus in the Perlin lab is on fungal and bacterial drug discovery, mechanisms of drug resistance and virulence in fungal pathogens, and development of rapid diagnostics for these life-threatening infections (for more information see https://hmh-cdi.org/our-labs/perlin-lab/perlin-research). The ideal candidate will have a Ph.D. in molecular biology, cell biology, genetics, microbiology, or related discipline, extensive expertise in molecular biology, genetics, and genomics, and a strong interest in infectious disease research, particularly mechanisms driving the emergence of drug resistant mutants. For consideration, please email your CV and information on three references to firstname.lastname@example.org and email@example.com.
Hackensack Meridian Health is a leading not-for-profit health care organization that is the largest, most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care. Hackensack Meridian Health comprises 17 hospitals from Bergen to Ocean counties, which includes three academic centers, including the new Hackensack Meridian Health School of Medicine a Seton Hall, as well as more than 500 patient care center throughout the state medical centers.